[go: up one dir, main page]

MXPA04000340A - FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN. - Google Patents

FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN.

Info

Publication number
MXPA04000340A
MXPA04000340A MXPA04000340A MXPA04000340A MXPA04000340A MX PA04000340 A MXPA04000340 A MX PA04000340A MX PA04000340 A MXPA04000340 A MX PA04000340A MX PA04000340 A MXPA04000340 A MX PA04000340A MX PA04000340 A MXPA04000340 A MX PA04000340A
Authority
MX
Mexico
Prior art keywords
cetuximab
fatty acid
acid ester
polyoxyethylene sorbitan
liquid formulation
Prior art date
Application number
MXPA04000340A
Other languages
English (en)
Inventor
Mahler Hanns-Christian
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA04000340A publication Critical patent/MXPA04000340A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se relaciona con una formulacion farmaceutica liquida estable que comprende Cetuximab(r), un anticuerpo monoclonal quimerico contra el receptor del factor de crecimiento endotelial (receptor EGF). La formulacion tiene una mayor estabilidad de almacenamiento y puede usarse por via parenteral para el tratamiento de tumores.
MXPA04000340A 2001-07-13 2002-06-18 FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN. MXPA04000340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab
PCT/EP2002/006696 WO2003007988A1 (de) 2001-07-13 2002-06-18 Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitanfettsäureester

Publications (1)

Publication Number Publication Date
MXPA04000340A true MXPA04000340A (es) 2004-05-04

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000340A MXPA04000340A (es) 2001-07-13 2002-06-18 FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN.

Country Status (18)

Country Link
US (1) US20040170632A1 (es)
EP (1) EP1406658A1 (es)
JP (1) JP2004536129A (es)
KR (1) KR20040018458A (es)
CN (1) CN1231264C (es)
AR (1) AR039358A1 (es)
BR (1) BR0211060A (es)
CA (1) CA2453342A1 (es)
CZ (1) CZ2004189A3 (es)
DE (1) DE10133394A1 (es)
HU (1) HUP0401046A3 (es)
MX (1) MXPA04000340A (es)
PE (1) PE20030433A1 (es)
PL (1) PL364599A1 (es)
RU (1) RU2004102395A (es)
SK (1) SK862004A3 (es)
WO (1) WO2003007988A1 (es)
ZA (1) ZA200401161B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO346070B1 (no) * 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
JP2007522157A (ja) * 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
MXPA06012145A (es) * 2004-04-27 2007-01-31 Wellstat Biologics Corp Tratamiento del cancer utilizando virus y camptotecinas.
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
CN101163468A (zh) * 2005-02-28 2008-04-16 卫材R&D管理有限公司 磺酰胺化合物的新联合用途
EP1982718A4 (en) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
CA2650953A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
JP5631591B2 (ja) * 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
KR20210088528A (ko) * 2018-08-31 2021-07-14 앰플릭스 파마슈티컬스, 인크. 진균 감염을 치료하기 위한 화합물 및 방법
TW202523354A (zh) * 2023-11-29 2025-06-16 大陸商四川科倫博泰生物醫藥股份有限公司 抗體製劑
WO2025245256A1 (en) 2024-05-22 2025-11-27 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable

Also Published As

Publication number Publication date
SK862004A3 (en) 2004-07-07
DE10133394A1 (de) 2003-01-30
ZA200401161B (en) 2004-10-22
PE20030433A1 (es) 2003-05-24
US20040170632A1 (en) 2004-09-02
CZ2004189A3 (cs) 2004-05-12
RU2004102395A (ru) 2005-05-27
CA2453342A1 (en) 2003-01-30
BR0211060A (pt) 2004-07-20
JP2004536129A (ja) 2004-12-02
HUP0401046A3 (en) 2006-11-28
CN1527724A (zh) 2004-09-08
HUP0401046A2 (en) 2006-04-28
EP1406658A1 (de) 2004-04-14
KR20040018458A (ko) 2004-03-03
WO2003007988A1 (de) 2003-01-30
CN1231264C (zh) 2005-12-14
PL364599A1 (en) 2004-12-13
AR039358A1 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
MXPA04000340A (es) FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN.
MY139055A (en) Lyophilised preparation containing antibodies to the egf receptor
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
PT1412384E (pt) Formulação estável de glp-1 modificado
AU2001231763A1 (en) Dosing regimen
AU2000233235A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
MXPA03004780A (es) Nuevas sulfamidas.
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
YU78202A (sh) Tečne formulacije
PH12013500225A1 (en) Stabilized formulations containing anti-ngf antibodies
JO3000B1 (ar) مركبات أجسام مضادة .
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
TW200736277A (en) RANKL antibody-PTH/PTHrP chimeric molecules
CA2446192A1 (en) Apparatus and method for wetting powder
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
ATE453382T1 (de) Pulver zur nasalen verabreichung von wirkstoffen
AU2003205768A1 (en) Methods and compositions for treating hyperproliferative conditions
AP1696A (en) Agrochemical formulations comprising ALS inhibitors.
MXPA03011059A (es) Procedimiento para dosificar un combustible con un aditivo de combustible.